This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BI655066, BI-655066, Risankizumab, BI 655066, ABBV066, ABBV 066
Description: BI 655066 is an anti-IL-23 monoclonal antibody specific for the p19 subunit.
Abbvie and Boehringer
In March 2016, AbbVie and Boehringer Ingelheim announced a global collaboration to develop and commercialize BI 655066. AbbVie and Boehringer Ingelheim also are evaluating the potential of this biologic therapy in Crohn's disease, psoriatic arthritis and asthma. In addition, AbbVie gains rights to BI 655064. Boehringer Ingelheim will retain responsibility for further development of BI 655064, and AbbVie may elect to advance the program after completion of certain undisclosed clinical achievements.
Under the terms of the license agreement, AbbVie will make an initial upfront payment of $595 million. Boehringer Ingelheim will be eligible to receive additional development and regulatory milestone payments and royalties on net sales, the terms of which are not disclosed. In the initial period, the Companies will share the responsibility for future development of BI 655066. AbbVie will be solely responsible for commercialization of BI 655066, while...See full deal structure in Biomedtracker
Partners: Boehringer Ingelheim GmbH
Additional information available to subscribers only: